Validation of cytogenetic risk groups according to international prognostic scoring systems by peripheral blood cd34+fish: Results from a german diagnostic study in comparison with an international control group

Haematologica

Volumn 100, Issue 2, 2015, Pages 205-213

  Braulke, Friederike ^a   Platzbecker, Uwe ^b   Müller Thomas, Catharina ^c   Götze, Katharina ^c   Germing, Ulrich ^d   Brümmendorf, Tim H ^e   Nolte, Florian ^f   Hofmann, Wolf Karsten ^f   Giagounidis, Aristoteles A N ^g   Lübbert, Michael ^h   Greenberg, Peter L ⁱ   Bennett, John M ^j   Solé, Francesc ^k   Mallo, Mar ^k   Slovak, Marilyn L ^l   Ohyashiki, Kazuma ^m   Le Beau, Michelle M ⁿ   Tüchler, Heinz ^o   Pfeilstöcker, Michael ^o   Nösslinger, Thomas ^o   Hildebrandt, Barbara ^d   Shirneshan, Katayoon ^a   Aul, Carlo ^p   Stauder, Reinhard ^q   Sperr, Wolfgang R ^r   Valent, Peter ^r   Fonatsch, Christa ^r   Trümper, Lorenz ^a   Haase, Detlef ^a   Schanz, Julie ^a   more..

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g MARIEN HOSPITAL DÜSSELDORF   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^k JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^l SONORA QUEST LABORATORIES   (United States)

^m TOKYO MEDICAL UNIVERSITY   (Japan)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o HANUSCH HOSPITAL   (Austria)

^p ST JOHANNES HOSPITAL   (Germany)

^q INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROSPECTIVE STUDY; VALIDATION PROCESS; VERY ELDERLY;

EID: 84964301286     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.110452     Document Type: Article

References (26)

1. Silverman LR. Neoplasms of the hematopoietic system: myelodysplastic Syndrome, In: Holland J, Frei EI, Bast RJ, eds. Cancer Medicine. Hamilton, Canada, BC Decker. 2000:1931-1946.
2. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol. 2004;41:6-12.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplstic syndromes. Blood. 1997;89:2079-2088.
4. Haase D, Germing U, Schanz J, et al. New insights into prognostic impact of the kary-otype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385-4395.
5. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
6. Schanz J, Tüchler H, Solé F, Mallo M, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-829.
7. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3): 223-232.
9. Rigolin GM, Bigoni R, Milani R, et al. Clinical imprtance of interphase cytogenet-ics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia. 2001;15:1841-57.
10. Romeo M, Chauffaille Mde L, Silva MR, Bahia DM, Kerbauy J. Comparison of cytoge-netics with FISH in 40 myelodysplastic syndrome patients. Leuk Res. 2002;26:993-996.
11. Yang W, Stotler B, Sevilla DW, et al. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res. 2010;34:420-425.
12. Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from working conference. Leuk Res. 2007; 31:727-736.
13. Braulke F, Schanz J, Jung K, et al. FISH Analysis of Circulating CD34+ Cells as a New Tool for Genetic Monitoring in MDS: Verification of the Method and Application to 27 MDS Patients. Leuk Res. 2010; 34:1296-1301.
14. Braulke F, Jung K, Schanz J, et al. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study. Leuk Res. 2013;37:900-906.
15. Cherry AM, Slovak ML, Campbell LJ, et al. Will a peripheral blod (PB) sample yield the same diagnostic and prognostic cytoge-netic data as the concomitant bone marrow (BM) in myelodysplasia? Leuk Res. 2012; 36:832-840.
16. Shaffer LG, McGowan-Jordan J, Schmid M (eds): An international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S. Karger A.G: Basel, 2013.
17. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lym-phoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. Hematol J. 2000;1(1):53-66.
18. Mishra A, Corrales-Yepez M, Ali NA, et al. Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Am J Hematol. 2013,88(7):566-570.
19. Sekeres M, Ades L, Tuechler H, et al. Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM. Leuk Res. 2013;37:113(abstract 113).
20. Breccia M, Salaroli A, Loglisci G, Alimena G. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azaciti-dine. Ann Hematol. 2013;92(3):411-412.
21. Schanz J, Steidl C, Fonatsch C, et al. Coalesced Multicentric Analysis of 2351 Patients with Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. J Clin Oncol. 2011; 29:1963-1970.
22. Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multi-centre study. Leuk Res. 2014;38:57-64.
23. Coleman JF, Theil KS, Tubbs RR, Cook JR. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. Am J Clin Pathol. 2011;135(6):915-920.
24. Costa D, Valera S, Carrió A, et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? Leuk Res. 2010;34:1437-1441.
25. Jiang H, Xue Y, Wand Q, et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. Leuk Res. 2012;36:448-452.
26. Pinheiro R F, Chauffaille MLLF. Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome.